$OCGN (OCUGEN) — 8-K: Ocugen targets three BLA submissions by 2028 across Stargardt, dAMD, and RP

Ocugen’s September 2026 pipeline update shows Phase 2/3 enrollment completed for OCU410ST in Stargardt disease with a target BLA submission in mid-2027. OCU410 for geographic atrophy is set to begin Phase 3 in 3Q 2026, and OCU400 for retinitis pigmentosa has completed Phase 3 enrollment with a target BLA submission in 2Q 2027. The company is positioning three ophthalmology gene therapy programs for regulatory filings by 2028.

Ocugen’s September 2026 pipeline update shows Phase 2/3 enrollment completed for OCU410ST in Stargardt disease with a target BLA submission in mid-2027. OCU410 for geographic atrophy is set to begin P